These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6105670)

  • 41. Full remission of tardive dyskinesia following general anaesthesia.
    Johnsen M; Wester K
    J Neurol; 2002 May; 249(5):622-5. PubMed ID: 12021954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
    Hyttel J
    Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
    [No Abstract]   [Full Text] [Related]  

  • 43. Theoretical implications of tolerance development in DA, ACh and GABA turnover after neuroleptic chronic treatment.
    Agnati LF; Zini I; Lenzi P; Cortelli P; Battistini N; Bernardi P
    Boll Soc Ital Biol Sper; 1981 Jun; 57(11):1261-6. PubMed ID: 6116494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The receptor-binding profile of neuroleptic agents].
    Eneman M
    TVZ; 1990 Feb; (3):89-93. PubMed ID: 1969274
    [No Abstract]   [Full Text] [Related]  

  • 45. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Physiopathology and treatment of tardive dyskinesia].
    Cai N; Song TS
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):252-5. PubMed ID: 3000711
    [No Abstract]   [Full Text] [Related]  

  • 47. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case report of adverse effect of reserpine on tardive dyskinesia.
    Donatelli A; Geisen L; Feuer E
    Am J Psychiatry; 1983 Feb; 140(2):239-40. PubMed ID: 6129810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current status of our knowledge of the neurotropic side effects of neuroleptic drugs].
    Sabbatini F; Pinessi L; Gentile S; De Mattei M; Portaleone P
    Minerva Psichiatr; 1983; 24(4):145-53. PubMed ID: 6145083
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
    Noda Y; Kurumiya S; Miura Y; Oka M
    J Pharmacol Exp Ther; 1993 May; 265(2):745-51. PubMed ID: 8098763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain iron, dopamine receptor sensitivity, and tardive dyskinesia.
    Blinder BJ; Goodman S; Youdim MB
    Am J Psychiatry; 1986 Feb; 143(2):277-8. PubMed ID: 2868669
    [No Abstract]   [Full Text] [Related]  

  • 53. Receptors, neurotransmitters and drug responses.
    Snyder SH
    N Engl J Med; 1979 Mar; 300(9):465-72. PubMed ID: 32488
    [No Abstract]   [Full Text] [Related]  

  • 54. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
    Bacopoulos NG
    J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.
    Rastogi SK; Rastogi RB; Lapierre YD; Singhal RL
    Gen Pharmacol; 1982; 13(6):499-504. PubMed ID: 7152230
    [No Abstract]   [Full Text] [Related]  

  • 56. Mesolimbic system and tardive dyskinesia: new perspectives for therapy.
    Cools AR
    Mod Probl Pharmacopsychiatry; 1983; 21():111-23. PubMed ID: 6140628
    [No Abstract]   [Full Text] [Related]  

  • 57. [Neuroleptic-induced dopaminergic supersensitivity following intermittent and continuous haloperidol administrations in rats].
    Sato M; Kashihara K; Harada T
    Seishin Shinkeigaku Zasshi; 1984; 86(10):841-4. PubMed ID: 6522512
    [No Abstract]   [Full Text] [Related]  

  • 58. Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
    Wray SR; Melville GN; Grell GA; Edge PC
    West Indian Med J; 1981 Sep; 30(3):107-18. PubMed ID: 6117153
    [No Abstract]   [Full Text] [Related]  

  • 59. Current psychopathological theories of tardive dyskinesia and their implications for future research.
    Ananth J
    Neuropsychobiology; 1982; 8(4):210-22. PubMed ID: 6127649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Correlation of dopamin- and GABA-ergic mechanisms in the depressive effect of neuroleptics on pedal self-stimulation of the ventral tegmentum of the mesencephalon].
    Talalaenko AN; Boreĭsha IK
    Farmakol Toksikol; 1983; 46(2):36-9. PubMed ID: 6133777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.